Pacific Biosciences of California, Inc.

PACB Healthcare Medical Devices

Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024. In the quarter to June 2026, revenue fell 1.91%, EPS was flat, free cash flow fell 31.0% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.73 0.23 −11.73%
Market cap
$609.2M
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
3/9
Altman Z
−6.04
Beneish M
−5.14
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 5 3 3

+8 more TTM periods

ROE
(929.31%) (273.55%) (213.45%) (205.90%)
ROA
(16.66%) (15.65%) (53.45%) (44.70%)
ROIC
(22.22%) 0.00% (93.25%) (108.83%)
Return on Tangible Assets
(44.27%) (39.14%) (167.41%) (142.61%)
Average Days of Receivables
71.28 66.94 80.86 72.29
Free Cash Flow per Share
(0.26) (0.23) (0.40) (0.44)
Free Cash Flow
(80.48) (71.21) (118.92) (131.44)
Other line items

Show all line items

Columns are period end dates